231 related articles for article (PubMed ID: 33543027)
1. Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas.
El-Nadi M; Hassan H; Saleh ME; Nassar E; Ismail YM; Amer M; Greve B; Götte M; El-Shinawi M; Ibrahim SA
Matrix Biol Plus; 2020 May; 6-7():100030. PubMed ID: 33543027
[TBL] [Abstract][Full Text] [Related]
2. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
[TBL] [Abstract][Full Text] [Related]
3. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
4. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.
Mohamed MM; El-Ghonaimy EA; Nouh MA; Schneider RJ; Sloane BF; El-Shinawi M
Int J Biochem Cell Biol; 2014 Jan; 46():138-47. PubMed ID: 24291763
[TBL] [Abstract][Full Text] [Related]
5. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Breast Cancer: The Secretome of HCMV
Mohamed HT; El-Sharkawy AA; El-Shinawi M; Schneider RJ; Mohamed MM
Front Oncol; 2022; 12():899622. PubMed ID: 35847899
[TBL] [Abstract][Full Text] [Related]
7. Heparanase is a novel biomarker for immune infiltration and prognosis in breast cancer.
Yang WJ; Shi L; Wang XM; Yang GW
Aging (Albany NY); 2021 Aug; 13(16):20836-20852. PubMed ID: 34461608
[TBL] [Abstract][Full Text] [Related]
8. Role of adipose tissue-derived cytokines in the progression of inflammatory breast cancer in patients with obesity.
Ibrahim AS; El-Shinawi M; Sabet S; Ibrahim SA; Mohamed MM
Lipids Health Dis; 2022 Aug; 21(1):67. PubMed ID: 35927653
[TBL] [Abstract][Full Text] [Related]
9. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
[TBL] [Abstract][Full Text] [Related]
10. [Influence of the HLDF differentiation factor on the production of cytokines by bio-tissues of breast tissue in its non-malignant diseases and in invasive carcinoma of a non-specific type].
Autenshlyus AI; Studenikina AA; Mikhaylova YS; Proskura AV; Varaksin NA; Sidorov SV; Bogachuk AP; Lipkin VM; Lyakhovich VV
Biomed Khim; 2020 Nov; 66(6):485-493. PubMed ID: 33372907
[TBL] [Abstract][Full Text] [Related]
11. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
12. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
Xiang J; Lu M; Shi M; Cheng X; Kwakwa KA; Davis JL; Su X; Bakewell SJ; Zhang Y; Fontana F; Xu Y; Veis DJ; DiPersio JF; Ratner L; Sanderson RD; Noseda A; Mollah S; Li J; Weilbaecher KN
J Virol; 2022 Apr; 96(7):e0005722. PubMed ID: 35319225
[TBL] [Abstract][Full Text] [Related]
13. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
[TBL] [Abstract][Full Text] [Related]
14. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer.
Rahal OM; Wolfe AR; Mandal PK; Larson R; Tin S; Jimenez C; Zhang D; Horton J; Reuben JM; McMurray JS; Woodward WA
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1034-1043. PubMed ID: 29485045
[TBL] [Abstract][Full Text] [Related]
15. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
17. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
Kelly T; Suva LJ; Huang Y; Macleod V; Miao HQ; Walker RC; Sanderson RD
Cancer Res; 2005 Jul; 65(13):5778-84. PubMed ID: 15994953
[TBL] [Abstract][Full Text] [Related]
18. Interleukin‑17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer.
Lv Q; Wu K; Liu F; Wu W; Chen Y; Zhang W
Int J Oncol; 2018 Oct; 53(4):1809-1817. PubMed ID: 30066843
[TBL] [Abstract][Full Text] [Related]
19. The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients.
Saleh ME; Gadalla R; Hassan H; Afifi A; Götte M; El-Shinawi M; Mohamed MM; Ibrahim SA
PLoS One; 2019; 14(5):e0217550. PubMed ID: 31145753
[TBL] [Abstract][Full Text] [Related]
20. XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant.
Van Berckelaer C; Van Laere S; Lee S; Morse MA; Geradts J; Dirix L; Kockx M; Bertucci F; Van Dam P; Devi GR
Transl Oncol; 2024 May; 43():101907. PubMed ID: 38412664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
